Vanda Pharmaceuticals, Inc.
9620 Medical Center Drive
About Vanda Pharmaceuticals, Inc.Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.
Founders: Mihael Hristos Polymeropoulos, Argeris Karabelas
CEO: Mihael Hristos Polymeropoulos
CFO: James Kelly
Please click here for Vanda job opportunities.
Please click here for clinical trial information.
311 articles with Vanda Pharmaceuticals, Inc.
Vanda Applauds White House Issuance of Executive Orders Requiring Federal Agencies to be Transparent in Policymaking and Enforcement
The recent Executive Orders appropriately identify the issues associated with the issuance of guidance documents.
Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, commends the U.S. Environmental Protection Agency (EPA) for yesterday's pledge "to aggressively reduce animal testing" with the goal of "completely eliminating them by 2035.
8/23/2019Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments.
Vanda Pharmaceuticals Announces the Appointments of a Chief Corporate Affairs and Communications Officer and a Chief Marketing Officer
Vanda Pharmaceuticals Inc. announced that it has named Aranthan "AJ" Jones II as its Chief Corporate Affairs and Communications Officer and Joakim "Kim" Wijkstrom as its Chief Marketing Officer.
Vanda Pharmaceuticals Inc. announced that on August 16 2019, it received a Complete Response Letter from the U.S. Food and Drug Administration as part of its ongoing review of Vanda's supplemental New Drug Application for HETLIOZ® for the treatment of Jet Lag Disorder.
Now that July has come and gone, the U.S. Food and Drug Administration is back to work approving drugs. This week marks three PDUFA target action dates, although one has already been rejected and another hit a snag that doesn’t appear to affect the decision date.
Vanda Pharmaceuticals Inc. announced financial and operational results for the second quarter ended June 30, 2019.
As 2019 enters its second half, BioSpace takes a look at some of the warning letters issued by the U.S. Food and Drug Administration to the biopharma industry.
Vanda Pharmaceuticals Inc. announced that on July 19, 2019, it received a notification from the U.S. Food and Drug Administration stating that as part of its ongoing review of Vanda's supplemental New Drug Application for HETLIOZ® for the treatment of Jet Lag Disorder, the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2019 on Wednesday, July 31, 2019, after the market closes.
Vanda Pharmaceuticals Inc. announced that tradipitant, a neurokinin-1 receptor antagonist, was effective in treating motion sickness in a clinical study conducted in the Pacific Ocean.
The corporate presentation at the JMP Securities Life Sciences Conference will be available live on Vanda's corporate website, where it also will be archived for 30 days.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that Mihael H. Polymeropoulos, co-founder and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference in New York City on Tuesday, June 4, 2019
Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week® (DDW) 2019 in San Diego, CA.
Total net product sales of $47.7 million in the first quarter of 2019, a 9% increase year over year
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that Phaedra Chrousos has joined Vanda's Board of Directors, effective April 23, 2019.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2019 on Wednesday, May 1, 2019, after the market closes.
Hagens Berman Reminds Vanda Pharmaceuticals (VNDA) Investors of April 26, 2019 Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
Hagens Berman Sobol Shapiro LLP reminds investors in Vanda Pharmaceuticals Inc. of the April 26, 2019 Lead Plaintiff deadline in the pending securities class action.
VNDA LAWSUIT ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. - VNDA
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Vanda Pharmaceuticals Inc. from November 4, 2015 through February 11, 2019, inclusive.
Vanda Pharmaceuticals Inc., announced that it will deliver a corporate presentation at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts on Monday, March 11, 2019 at 1:30 p.m. Eastern Time.